THE STEROID HORMONAL n I m u OF THE HUHAN FETUS AND MOTHER AT 16-20 UEEKS OF GESTATION.
The inter-relations of steroid hornone levels in plasma from mothers and their undisturbed fetuses during the second trimester of human pregnancy have not been defined previously. Haternal vein (MV), fetal artery (FA), fetal vein (FV) and amniotic fluid (AP) levels of progesterone (P), 17-OHP, 11 deoxycortisol (S), DOC, cortisone (E) , cortisol (F) , corticosterone (B) and aldosterone (Aldo) were measured in microassays in 12 conscious but sedated mothers and their fetuses undergoing therapeutic termination of pregnancy at 16-20 weeks gestation. The study received the approval of the Hospital Ethical Committee and maternal consent for the studies was obtained in each case. FA and W samples were obtained by direct vessel puncture through a fetoscope without fetal disturbance. FA levels of P and B were eignificantly higher (~(0.01) than in W ; W levels of P and E were higher (p<0.01) than FA values. No significant differences between FV or FA were found for levels of DOC. 17-OHP or S. MV levels of Aldo, P and B were significantly higher, with values of P, 17-OHP.
WC and S significantly lovqr than those in either fetal vessel.
AP values of F. B, S. Aldo and DOC tended to be lower than those reported previously from mothers undergoing routine amniocentesis. We conclude: there is evidence that the fetal adrenal cortex is functioning independently of the mother in mid-gestation; maternal premeditation ray lower fetal stress hormone secretion. and 20-34 weeks periods. A significant relationship between AF levels and age of pregnancy could only be detected for GAldo (r= 0.691, p<0.01). Our results agree with patterns of PAldo (Weir et al, 1974 , Ledoux et al, 1975 and FAldo (Blankstein et al, 1980 , Sippell et al, 1981 already reported. The increase of GAldo presently described disagrees with its high andstable level reported by Aderjan et a1 (1977) on poorly documented data. Simultaneous determination of F-and G-Aldo shows that the rate of increase of fetal aldosterone production is higher than could be expected fram estimation of FAldo alone. Augmentation of GAldo in AF probably expresses both the increased contribution of urine to AF and the maturation of renal glycuronoconjugation process. 0epartmen; of Pediatrics,University Hospital H d u r g . W -G e m n y Water Metabolism in Preterm Infants during the first Week of Life and its Regulation by ArginineVasopressin(AVP1. We studied the m l e of AVP in the water metabolism of preterm infants with a sensitive urinary AVP RIA.Three groups were studie d.GmupA:16 orally fed infants f m m 32 to 38 weeks of gestation. GmupB:6 infants with parenteral fluid adninistration f n m 32 to 36 weeks of gestation.GmupC:?2 infant~~ventilated for ROS f m 28 to 36 weeks of gestation with parenteral fluid adninistration. Gr.A received 50f9 rnl/kg on day 1 with daily increasing mounts -up to 169217 rnlAg on day 7 p.o.They had s m l l urine volumes with high omlality and lost up to 9% weight.AVP was stimulated by this water loss f m 15.3+4.3pg/rnl on day 1 to 36.6+27.2pg/rnl on day 3-5.G1-8 received initially greater fluid volumes i.v.(109+10 rnl/kg onday 11 .They pmduced m r e urine with low ovnolality and did not loose weight.AVP was suppressed f m 13.1+11.4pg/ml on day 1 to 5.4+3.5pg/rnl on day 2.GrC received on day 1 already 121 +Zlrnl/kg.~he-infants gained weight up to 107.5+6.3% on day 3while -s e m Na decreased to 133 ml/l.Urine volume Gas inadequate low as was urine ovnolality inadequate high.AVP was 21.0+18.7pg/rnl on day 1 and was not suppressable until day 3.There was a significant (p=D.D5)correlation between IrninApgar scores and AVP as well as Fi02 and AVP on day 1.No significant correlation was found between m a n respiratory pressure and AVP.We conclude,that infants with RDS have a nonosnotic release of AVP and should receive smller fluid volumes in the first three days of life. A paradoxical GH response to TRH has been described in constitutional tall'stature. Bromocriptine (BR) therapy has consequently been proposed to reduce adult height prediction in tall but otherwise normal children. This study evaluates the GH response (0-180min) to a single dose (0.2mg) of TRH (n=59) in 11 tall children followed prospectively before (Al) and after (A2) 6 months of treatment with BR (5mg/d), while still on therapy, in 9 children of average height (B), 12 with precocious puberty (C), 9 with delayed puberty (Dl and 7 with GH deficiency (E). Peaks of GH ( > Sng/ml) were observed in 92.3% of cases from groups A to D, whereas none occurred in group E. They occurred mainly beyond 120 minutes (57.6%) and were of similar magnitude in groups Al, A2 and B.,In addition, a bifid secretion pattern occurred in 43.5% of cases. In these patients, the early peak was unrelated to stress (normal prolactin). In conclusion, the mode of GH response as well as GI3 peak amplitude following TRB remain similar in tall and in average height children who are matched for bone age. In group A2, BR failed to modify the GH secretory pattern following TRH injection. The pattern of GH secretion observed after TRH might be the expression of its normal amplified pulsatile secretion mode during puberty and thus be independent of TRH.
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THE MECHANISM OF THE ADOLESCENT GROWTH SPURT INDUCED BY PULSATILE GnRH TREATMENT
We have induced puberty in 26 patients (12M, 14F) using low dose pulsatile GnRH for 0.8 to 1.6 years. Progress was monitored by serial overnight profiles for gonadotrophins, GH and sex steroids at 15 minute intervals. GlRH 2 or 4ugs was administered subcutaneously at night at 90 minute intervals. In order to maintain normal pubertal development, GnRH pulse amplitude was progressively increased and/or treatment was administered throughout 24 hrs. We have succeeded in mimicking all the endocrine and clinical events of puberty including the timings of the adolescent growth spurts.
Girls showed early growth acceleration with an increase in GH secretion from the first week of treatment. After breast stage 4 had been attained, GH pulse amplitude varied with the state of ovarian follicular development. By contrast, boys showed a decelerating growth velocity and diminishing GH pulse amplitude at the start of treatment, even though sex steroid secretion increased progressively. When a l b l testicular volume had been attained there was a marked increase in GH pulse amplitude coincident with the pubertal growth spurt. In both sexes GH secretion was modulated by changes in pulse amplitude without alteration in pulse frequency.
These observations explain the differences in timings of the onset of the adolescent growth spurts of girls and boys. All 15 patients with PRGHD remained GH deficient [peak GH level <7mU/1 (n=lD) and 7-15mU/1 (n=5)].
However of the 19 retested IGHD patients, 5 (26%) had peak GH responses >15mU/1 (regarded now as transient or false F-IGD) and were indistinguishable from the remainder [permanent or true T-IGHD, peak GH levels <7mU/1 (n-12) and 7-15 mU/1 (n=2)1 by pre-treatment anthropometry and post-treatment height SDS, but had a lower first year height velocity (Mean Velocity 5.4cm/yr iD.9 for F-IGHD v 8.7cm/year i1.75 for T-IGHD p<0.01) and helght acceleration on treatment (Mean acceleration Z.lcm/yr i1.7 for F-IGHD v 5.2cm/yr k2.3 for T-IGHD p<0.05).
Ely current practices 2 F-IGHD patients may have been distinguished by sex-sterold priming.
Thus post-irradlation GH deficiency appears to be permanent but errors of diagnosis in IGHD are common.
